NIPH Clinical Trials Search

Study of fluorouracil, epirubicin and cyclophosphamide followed by docetaxel as preoperative chemotherapy in primary breast cancer (JBCRG-02)

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	Primary breast cancer
Date of first enrollment	2004/08/01
Target sample size	30
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2, q3w x 4 cycles, followed by Docetaxel 100 mg/m2, q3w x 4 cycles as Primary systemic Chemotherapy

Outcome(s)

Primary Outcome	Safety, clinical and histologic effect
Secondary Outcome	Breast-conserving rate, disease-free survival

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	60years-old
Gender	Female
Include criteria
Exclude criteria	Hypersensitivity for drug Serious coexisting illness Active double cancer Bilateral breast cancer Male breast cancer Pregnant or postpartum women